Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 12/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.35 |
| ▸ | CTSA | P10619 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18713622 | 0.93 | P2RX3 (0.38) | P2RX3SLC6A4TRPV3FFAR4CTSA | |
| SCHEMBL20032145 | 0.88 | CSNK2A1 (0.40) | P2RX3 | |
| SCHEMBL20032482 | 0.83 | TRPV1 (0.36) | SLC6A4CTSA | |
| SCHEMBL18713568 | 0.81 | CSNK2A1 (0.43) | P2RX3 | |
| SCHEMBL18713738 | 0.81 | PTGS2 (0.41) | CTSA | |
| SCHEMBL20032498 | 0.79 | CNR1 (0.45) | P2RX3TRPV3FFAR4 | |
| SCHEMBL21366928 | 0.79 | KCNH2 (0.43) | — | |
| SCHEMBL20032371 | 0.79 | KCNH2 (0.40) | — | |
| SCHEMBL18713973 | 0.77 | KCNH2 (0.40) | CTSA | |
| SCHEMBL16574085 | 0.76 | KCNQ3 (0.39) | P2RX3TRPV3FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10350208-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | ROIVANT SCIENCES GMBH (CH) | 2019-07-16 | — | — | US | disclosed |
| US-20180092918-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | ALTAVANT SCIENCES GMBH (CH) | 2018-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180092918-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | TPH1, TPH2, HTR1A | P2RX3 1431/4885SLC6A4 19/4885TRPV3 640/4885 |
| US-10350208-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | TPH1, TPH2, HTR1A | P2RX3 1431/4885SLC6A4 19/4885TRPV3 640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.